Results 181 to 190 of about 311,294 (224)

[Amentoflavone alleviates acute lung injury in mice by inhibiting cell pyroptosis]. [PDF]

Nan Fang Yi Ke Da Xue Xue Bao
Sun Y, Luo M, Guo C, Gao J, Su K, Chen L, Feng X.   +6 more
europepmc   +1 more source

[SERPINE1 overexpression promotes proliferation and paclitaxel resistance of triple-negative breast cancer cells by inducing M2 macrophage polarization]. [PDF]

Nan Fang Yi Ke Da Xue Xue Bao
Zhang Q, Liu B, Lei L, Wang Y, Zhang X, Mao Z, Tang P, Zhang J, Yang J, Peng Y, Liu Z.   +10 more
europepmc   +1 more source

[Advances in complement inhibition therapy for paroxysmal nocturnal hemoglobinuria]. [PDF]

Zhonghua Xue Ye Xue Za Zhi
Shi YM, Zhang FK.
europepmc   +1 more source

[Kahweol improves motor function of mice with spinal cord injury by inhibiting microglial activation <i>via</i> regulating the IκBα/NF-κB pathway]. [PDF]

Nan Fang Yi Ke Da Xue Xue Bao
Xia J, Chen Y, Ren L, Li J, Song X, Tao L, Hu J.   +6 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

中国非小细胞肺癌免疫检查点抑制剂治疗专家共识（2020年版）

Zhongguo fei ai za zhi = Chinese journal of lung cancer, 2021
非小细胞肺癌（non-small cell lung cancer, NSCLC）是肺癌最常见的病理类型。晚期NSCLC的系统性抗肿瘤治疗经历了化疗、靶向治疗及免疫治疗的变革，患者总体生存时间不断延长。免疫检查点抑制剂（immune checkpoint inhibitors, ICIs），尤其是程序性死亡分子-1（programmed cell death protein 1, PD-1）/程序性死亡分子配体-1（programmed death-ligand 1, PD-L1 ...
Caicun Zhou, Jie Wang, Baocheng Wang, Ying Cheng, Zhehai Wang, B. Han, You Lu, Gang Wu, Li Zhang, Yong Song, B. Zhu, Yi Hu, Ziping Wang, Q. Song, S. Ren, Yayi He, Xiaohua Hu, Jian Zhang, Yu Yao, Hongyun Zhao, Zhijie Wang, Q. Chu, J. Duan, Jingjing Liu, S. Qin   +24 more
semanticscholar   +1 more source

PD-1单抗导致免疫检查点抑制剂相关肺炎1例——吡非尼酮治疗的安全性和有效性

Zhongguo fei ai za zhi = Chinese journal of lung cancer, 2021
背景与目的 免疫检查点抑制剂相关肺炎（checkpoint inhibitor pneumonitis, CIP）是严重的免疫检查点抑制剂副反应，急性期治疗手段已有共识，但急性期之后的肺间质纤维化治疗手段仍是临床需要解决的问题。 方法 回顾性分析了青岛市中心医院立体定向放疗科收治的1例细胞程序性死亡受体1（programmed cell death1, PD-1）单抗导致免疫检查点抑制剂相关肺炎的非小细胞肺癌（non-small cell lung cancer, NSCLC）患者的诊断、治疗过程 ...
Haiming Yu, Jinying Li, Lan Yu, Xi Cheng, Xiaona Han, Xiaotao Zhang   +5 more
semanticscholar   +1 more source

中国非小细胞肺癌免疫检查点抑制剂治疗专家共识（2019年版）

Zhongguo fei ai za zhi = Chinese journal of lung cancer, 2020
非小细胞肺癌（non-small cell lung cancer, NSCLC）是肺癌中最常见的病理类型，大多数NSCLC患者在确诊时已属晚期。对于驱动基因突变阴性的患者而言，目前的治疗仍以化疗为主，总体预后较差，改善治疗现状、获得长期生存是晚期NSCLC患者最迫切的需求。近年来，肿瘤免疫治疗发展迅速，免疫检查点抑制剂（immune checkpoint inhibitors, ICIs），尤其是以程序性死亡因子-1（programmed death-1, PD-1）/程序性死亡因子配体-1 ...
Caicun Zhou, Jie Wang, H. Bu, Baocheng Wang, B. Han, You Lu, Zhehai Wang, B. Zhu, Ziping Wang, Q. Song, S. Ren, D. Lin, Yayi He, Xiaohua Hu, Hongyun Zhao, S. Qin   +15 more
semanticscholar   +1 more source

肺癌免疫检查点抑制剂的联合治疗研究进展

Zhongguo fei ai za zhi = Chinese journal of lung cancer, 2020
检查点抑制剂（immune checkpoint inhibitors, ICIs）治疗是目前最常用的免疫治疗方案，已被批准用于黑色素瘤、肾癌、头颈癌、膀胱癌等多种肿瘤的临床治疗，在肺癌治疗中更是取得突破性进展，成为肺癌综合治疗的新支柱。但由于肿瘤的异质性及肿瘤微环境的复杂性，ICIs单药在非选择患者中有效率偏低。手术、化疗、放疗、靶向治疗等治疗手段可与免疫治疗产生协同作用，联合疗法成为目前探索的热点。本文着重于免疫检查点抑制剂联合治疗策略的研究进展，并描述了免疫疗法如何被用于早期癌症的治疗。
寒菲 Hanfei 郭 GUO, 日兰 Rilan 白 BAI, 久嵬 Jiuwei 崔 CUI   +2 more
semanticscholar   +1 more source

急性白血病患者化疗后骨髓抑制期血浆凝血因子XIII水平及其对出血事件的影响

Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi, 2020
目的 探讨急性白血病患者化疗后骨髓抑制期外周血凝血因子XIII（FXIII）浓度与出血事件的关系。 方法 ...
Yanzhi Wang, Bangyun Tan, Lin Li, Zijian Li   +3 more
semanticscholar   +1 more source